Lexicon Pharmaceuticals, Inc. — Q2 2012 Form 10-Q
Business context and period: Biopharmaceutical company focused on discovering and developing treatments, with five drug programs in clinical development. This unaudited filing covers the quarter and six months ended June 30, 2012; comparisons are with the corresponding 2011 periods.
Financial performance and position
| Metric | Q2 2012 | Six months 2012 |
|---|---|---|
| Revenue | $0.199 million | $0.499 million |
| Operating expenses | $25.679 million | $55.362 million |
| Operating loss | $25.480 million | $54.863 million |
| Net loss | $25.931 million | $55.799 million |
| Net loss per share | $0.05 | $0.12 |
| Operating cash used | $48.959 million for the six months |
- Revenue and margins: Revenue consisted mainly of collaborative research and license fees. With revenue very low relative to expenses, the company remained deeply loss-making; the filing does not present a meaningful positive operating margin.
- Liquidity: Cash and cash equivalents were $33.779 million at June 30, while short-term investments were $197.734 million, for total cash, cash equivalents and investments of $231.513 million. Total current assets were $238.277 million and current liabilities $21.555 million.
- Debt and other liabilities: Balance-sheet debt was $24.188 million, including $1.510 million current; the mortgage principal was $24.2 million at a fixed 8.23% rate. Total liabilities were $136.164 million. Other long-term liabilities included a $59.276 million fair-value estimate for Symphony Icon purchase consideration.
- Equity: Accumulated deficit was $845.420 million. The balance sheet reported 481.168 million shares issued at June 30; 494.336 million shares were outstanding as of July 31.
Changes versus prior comparable periods
- Q2 revenue fell 64% to $0.2 million; six-month revenue fell 57% to $0.5 million. Management attributed the decline mainly to lower U.S. Army Medical Research Acquisition Activity and functional genomics contract revenue, and reduced technology license fees.
- Research and development expense declined 4% in both the quarter and half-year, to $19.4 million and $42.4 million, respectively. Lower personnel and facilities costs partly offset higher external preclinical and clinical development costs.
- General and administrative expense decreased 8% in Q2 and 6% for the half-year. The Symphony Icon liability remeasurement expense increased to $4.2 million for the half-year from $2.9 million in 2011.
- Net loss narrowed modestly: $25.9 million versus $26.6 million for Q2, and $55.8 million versus $56.3 million for the half-year. Loss per share improved to $0.05 and $0.12, respectively, from $0.08 and $0.17; weighted-average shares were substantially higher in 2012.
- Cash and investments totaled $231.5 million, down from $281.7 million at year-end 2011. Cash and equivalents alone fell to $33.8 million, primarily as funds were shifted into short-term investments; investing activities used $102.7 million, including net investment purchases of $102.4 million.
Outlook, risks and unusual items
- Management expects significant continued R&D spending and ongoing losses, and says substantially all revenue has come from collaborations and licenses. Future revenue depends on new agreements, development milestones, collaborator performance and potential royalties.
- Management believes current unrestricted cash and investments, together with expected cash and revenue sources, will fund operations for at least the next 12 months. It cautions that additional equity, debt or credit financing may be needed thereafter and may be unavailable on acceptable terms.
- On July 30, 2012, after quarter-end, the company issued 13,237,519 shares to satisfy an additional $35 million Symphony Icon base payment obligation. The arrangement also includes up to $45 million in contingent payments, generally tied to specified licensing proceeds or U.S. regulatory approval.
- The Symphony Icon liability is a Level 3 fair-value estimate based on significant unobservable assumptions; its carrying value rose $4.243 million in the first half. This remeasurement is included in operating expense and is not itself a cash outflow for the period.
- The company reported no legal proceedings believed likely to have a material adverse effect. Principal risks include clinical and regulatory failure, reliance on collaborators and third-party manufacturers, financing needs, intellectual-property disputes, and stock-price volatility. Management reported disclosure controls were effective and no significant internal-control changes.
- No specific financial or product-development guidance was provided in the filing.
Important facts for investors to verify
- How the post-quarter issuance of 13.24 million shares affects dilution and the total shares outstanding.
- The timing and cash or stock implications of Symphony Icon base and contingent payments, and the assumptions underlying the Level 3 liability.
- Whether collaboration, license and milestone revenues can grow enough to offset continuing R&D spending and operating cash use.
- Whether management’s stated liquidity runway remains adequate given clinical-development costs and potential future financing needs.
- Progress, timelines and funding requirements for the five clinical-stage programs, including reliance on external research and manufacturing providers.